Takeda Pharmaceuticals International AG
Takeda Pharmaceutical Company Limited is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). Takeda also makes targeted R&D investments in Plasma-Derived Therapies and Vaccines.
Takeda are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Takeda employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.
Role within Screen4Care
Takeda is honored to co-lead WP1 in this project which deals with understanding the business and regulatory framework for rare disease screening in Europe. Takeda will contribute to all work packages to help provide more equitable access to diagnosis, treatment, care, and social opportunities for every patient. There will be with a higher resource emphasis in WP3 and WP4, which deal with the gene-panels and whole genome sequencing approach for genetic new-born screening and evidence based algorithms for early EHR-based rare disease detection.